<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width,initial-scale=1" />
  <title>GLP-1 &amp; GIP: Medications and Natural Incretin Support | Archangel Michael Health</title>

  <!-- Shared stylesheet -->
  <link rel="stylesheet" href="https://docbraymd.github.io/amh/style_v2.css" />

  <!-- html2pdf for one-click PDF download -->
  <script defer src="https://cdnjs.cloudflare.com/ajax/libs/html2pdf.js/0.10.1/html2pdf.bundle.min.js"></script>
</head>

<body>
  <div class="amh-page main-container" id="pdf-root" role="document">
    <header class="amh-header">
      <div class="amh-header-inner amh-header-centered">
        <div class="amh-logo-wrap">
          <img class="amh-logo" src="https://docbraymd.github.io/amh/AMHLogo.png" alt="Archangel Michael Health logo" />
        </div>

        <a href="https://archangelmichaelhealth.com/" class="amh-practice doctor-tag">Archangel Michael Health</a>

        <h1 class="amh-title" id="page-title">GLP-1 &amp; GIP: Medications and Natural Incretin Support</h1>
        <h2 class="amh-tagline">Patient Guide: Weight Loss, Prediabetes, and Metabolic Health</h2>
        <div class="byline">by Christopher L. Bray MD PhD</div>

        <div class="action-bar amh-actions no-print" aria-label="Actions">
          <button class="amh-btn amh-btn-secondary" type="button" onclick="window.print()">
            Print / Save as PDF
          </button>
          <button class="amh-btn amh-btn-primary" id="downloadPdfBtn" type="button">
            Download PDF
          </button>
        </div>
      </div>
    </header>

    <div class="amh-content content-body">
  <p>
    GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are naturally occurring gut hormones
    released after eating. They help coordinate appetite, blood sugar control, and energy balance. Modern “incretin” medications
    (GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists) leverage these pathways and can be highly effective for weight loss,
    prediabetes/type 2 diabetes management, and (for select therapies/indications) cardiometabolic risk reduction.
  </p>
  <p>
    Many lifestyle strategies—and a smaller, evidence-informed set of foods and supplements—can also support your body’s own incretin
    signaling. The effect size is typically smaller than prescription therapy, but the “foundations” often determine long-term success,
    including durability after medication changes.
  </p>

  <div class="toc no-print" aria-label="On this page">
    <h2>On this page</h2>
    <ul class="amh-list">
      <li><a href="#overview">Overview and key points</a></li>
      <li><a href="#symptoms">Symptoms and red flags</a></li>
      <li><a href="#diagnosis">Diagnosis and what to test</a></li>
      <li><a href="#drivers">Root causes and contributing factors</a></li>
      <li><a href="#consequences">Consequences and why early action matters</a></li>
      <li><a href="#plan">Step-by-step improvement plan</a></li>
      <li><a href="#treatments">Conventional treatments</a></li>
      <li><a href="#integrative">Integrative options</a></li>
      <li><a href="#costs">Cost considerations</a></li>
      <li><a href="#faq">FAQ</a></li>
      <li><a href="#references">References</a></li>
    </ul>
  </div>

  <h3 id="overview">Overview and key points</h3>

  <div class="clinical-note">
    <strong>High-yield summary:</strong>
    Incretin hormones rise after meals and help you handle glucose and calories more effectively. Incretin medications amplify these signals—often lowering appetite,
    slowing stomach emptying, and improving glucose-dependent insulin secretion. Natural approaches can support incretin biology, but the effect size is usually smaller.
    Durable results depend on protecting muscle, improving sleep/circadian rhythm, eating adequate protein and fiber, and reducing ultra-processed foods—not simply “taking something.”
  </div>

  <p>
    <strong>What GLP-1 does:</strong> promotes satiety (fullness), slows gastric emptying, enhances insulin secretion in a glucose-dependent manner,
    and helps regulate glucagon. These effects can reduce post-meal glucose excursions and lower “appetite drive.”
  </p>

  <p>
    <strong>What GIP does:</strong> also amplifies glucose-dependent insulin secretion and interacts with appetite and fat metabolism. In combination with GLP-1 pathway
    activation, GIP signaling can produce greater average weight loss than GLP-1 alone in many individuals.
  </p>

  <p>
    <strong>The clinical reality:</strong> In obesity and insulin resistance, satiety signaling often competes with a high-reward food environment, stress physiology,
    sleep disruption, and low muscle mass. Raising incretin signaling can create a window where sustainable behavior changes become more feasible.
  </p>

  <div class="clinical-note">
    <strong>Clinical note (how clinicians “frame” the problem):</strong>
    We typically evaluate (1) dysglycemia (A1c, fasting glucose, post-meal glucose), (2) insulin resistance/metabolic syndrome features
    (waist circumference, triglycerides/HDL, blood pressure, fatty liver markers), (3) cardiometabolic risk (ASCVD risk, sleep apnea, family history),
    and (4) secondary drivers (medications, endocrine disorders, circadian disruption). Treatment is then layered: foundations → targeted lifestyle → selective supplements → medications when indicated.
  </div>

  <h3 id="symptoms">Symptoms and red flags</h3>
  <p>
    Many people with insulin resistance or prediabetes feel “normal” until the problem is advanced. When symptoms do occur, they often reflect blood sugar variability,
    sleep disruption, or metabolic inflammation rather than a single specific complaint.
  </p>

  <ul class="amh-list symptom-list">
    <li><strong>Energy and cognition:</strong> afternoon fatigue, “brain fog,” or sleepiness after carbohydrate-heavy meals.</li>
    <li><strong>Hunger and cravings:</strong> strong appetite drive, frequent snacking, difficulty feeling satisfied, sweet cravings.</li>
    <li><strong>Weight pattern:</strong> gradual weight gain, especially abdominal/visceral fat; difficulty losing weight despite effort.</li>
    <li><strong>Glycemic symptoms (more advanced):</strong> increased thirst/urination, blurry vision, recurrent infections, slow wound healing.</li>
    <li><strong>Sleep-related:</strong> snoring, unrefreshing sleep, morning headaches (possible obstructive sleep apnea), evening overeating.</li>
    <li><strong>Women’s health:</strong> irregular cycles, acne, hirsutism (possible PCOS-related insulin resistance).</li>
  </ul>

  <div class="alert-box">
    <strong>Red flags (seek urgent care or prompt evaluation):</strong>
    severe, persistent abdominal pain (especially with vomiting) or pain radiating to the back; signs of dehydration (inability to keep fluids down,
    very low urine output, dizziness/fainting); black/tarry stools or vomiting blood; jaundice (yellow skin/eyes) or severe right-upper-quadrant pain;
    severe allergic reaction (hives, swelling, breathing difficulty); symptoms of severe hyperglycemia (confusion, rapid breathing, severe weakness),
    or low blood sugar (sweating, tremor, confusion) if you use insulin or sulfonylureas.
  </div>

  <h3 id="diagnosis">Diagnosis and what to test</h3>
  <p>
    The goal of testing is to (1) confirm where you are on the spectrum from normal glucose handling to diabetes,
    (2) identify cardiometabolic risk and complications early, and (3) look for treatable contributors that meaningfully change management.
  </p>

  <h4>Core “metabolic baseline” (common high-yield starting point)</h4>
  <ul class="amh-list">
    <li><strong>Hemoglobin A1c:</strong> estimates average glucose over ~3 months; interpret carefully in anemia or hemoglobin variants.</li>
    <li><strong>Fasting glucose:</strong> helps interpret A1c and screen for diabetes.</li>
    <li><strong>Fasting insulin (optional but useful):</strong> can help contextualize insulin resistance when interpreted carefully.</li>
    <li><strong>Comprehensive metabolic panel:</strong> kidney function and liver enzymes (fatty liver screening signal; medication safety baseline).</li>
    <li><strong>Lipid panel:</strong> triglycerides and HDL patterns are informative in insulin resistance; LDL/non-HDL guide ASCVD risk management.</li>
    <li><strong>Blood pressure and waist circumference:</strong> simple, high-value cardiometabolic markers.</li>
  </ul>

  <h4>Often useful add-ons (depending on context)</h4>
  <ul class="amh-list">
    <li><strong>Oral glucose tolerance test:</strong> clarifies post-meal glucose handling when fasting/A1c are borderline or discordant.</li>
    <li><strong>Continuous glucose monitoring (CGM):</strong> reveals glucose variability and meal responses; highly actionable for many motivated patients.</li>
    <li><strong>Urine albumin-to-creatinine ratio:</strong> screens for early kidney impact in diabetes/hypertension.</li>
    <li><strong>Thyroid testing (TSH ± free T4):</strong> if symptoms or risk factors suggest hypothyroidism contributing to weight gain/fatigue.</li>
    <li><strong>Sleep apnea evaluation:</strong> especially with snoring, daytime sleepiness, resistant hypertension, or elevated hematocrit.</li>
    <li><strong>Medication review:</strong> steroids, some antidepressants/antipsychotics, insulin secretagogues, and others can materially impact weight and glucose.</li>
  </ul>

  <div class="clinical-note">
    <strong>Interpreting “numbers” (practical anchors):</strong>
    For A1c, many clinicians use these thresholds: normal below 5.7%, prediabetes 5.7–6.4%, and diabetes 6.5% or higher (confirm when needed).
    Fasting glucose is often considered normal below 100 mg/dL, impaired fasting glucose 100–125 mg/dL, and diabetes 126 mg/dL or higher.
    Trajectory matters: the goal is to change the slope over time, not obsess over a single reading.
  </div>

  <h3 id="drivers">Root causes and contributing factors</h3>
  <p>
    Incretin biology does not operate in isolation. The “signal” of GLP-1/GIP is shaped by sleep and circadian rhythm, muscle mass,
    dietary pattern, stress physiology, and gut microbiome/metabolites. Sustainable improvement usually requires addressing the dominant drivers in your situation.
  </p>

  <ul class="amh-list symptom-list">
    <li><strong>Ultra-processed food exposure:</strong> hyperpalatable combinations (starch + fat + salt) can overwhelm satiety signaling.</li>
    <li><strong>Low protein / low fiber:</strong> reduces satiety and blunts meal-related gut hormone signaling; increases lean mass loss risk during weight loss.</li>
    <li><strong>Sleep and circadian misalignment:</strong> short sleep, irregular schedules, and late-night eating raise appetite drive and impair glucose handling.</li>
    <li><strong>Low muscle mass / low activity:</strong> skeletal muscle is a major glucose sink; resistance training improves insulin sensitivity and protects metabolism.</li>
    <li><strong>Stress and alcohol:</strong> stress hormones and alcohol both affect appetite, sleep, and liver fat; alcohol adds hidden calories and worsens reflux/nausea risk on therapy.</li>
    <li><strong>Medical contributors:</strong> hypothyroidism, PCOS, fatty liver, chronic inflammation, certain medications, and (less commonly) endocrine disorders.</li>
    <li><strong>Gut microbiome and bile acid signaling:</strong> fermentable fibers create short-chain fatty acids and bile-acid metabolites that may influence appetite and glucose regulation.</li>
  </ul>

  <h3 id="consequences">Consequences and why early action matters</h3>
  <p>
    Prediabetes and insulin resistance are not benign. Even before diabetes is diagnosed, metabolic dysfunction can contribute to vascular disease and organ stress.
    The earlier you address the root physiology, the more “reversible” the problem tends to be.
  </p>

  <ul class="amh-list">
    <li><strong>Progression to type 2 diabetes:</strong> higher A1c and greater glucose variability increase progression risk.</li>
    <li><strong>Cardiovascular disease:</strong> insulin resistance clusters with hypertension, adverse lipids, inflammation, and endothelial dysfunction.</li>
    <li><strong>Fatty liver (MASLD/NAFLD):</strong> common in insulin resistance and can progress to fibrosis in susceptible individuals.</li>
    <li><strong>Sleep apnea:</strong> both a contributor to and consequence of weight gain and metabolic dysfunction.</li>
    <li><strong>Kidney disease and neuropathy:</strong> risk rises as dysglycemia progresses and blood pressure remains uncontrolled.</li>
    <li><strong>Quality of life:</strong> fatigue, joint strain, reflux, and mood symptoms often improve when metabolic health improves.</li>
  </ul>

  <h3 id="plan">Step-by-step improvement plan</h3>

  <div class="success-box">
    <strong>Practical plan:</strong>
    Stabilize sleep/circadian rhythm and meal structure first, then build protein + fiber habits and resistance training, then add targeted tools (CGM, supplements, medications) based on response and risk.
  </div>

  <h4>Step 0: Define targets and how you will measure them</h4>
  <ul class="amh-list">
    <li><strong>Body composition:</strong> weight plus waist circumference; consider periodic body composition assessment (lean mass preservation matters).</li>
    <li><strong>Glycemic markers:</strong> A1c every 3–6 months; fasting glucose; CGM metrics if used (time-in-range and variability).</li>
    <li><strong>Cardiometabolic markers:</strong> blood pressure, triglycerides/HDL pattern, liver enzymes, sleep quality, stamina.</li>
    <li><strong>Behavioral markers:</strong> protein per meal, fiber per day, weekly resistance sessions, alcohol frequency, average sleep duration.</li>
  </ul>

  <h4>Step 1 (first 14 days): Build the “incretin-friendly” daily structure</h4>
  <ul class="amh-list">
    <li><strong>Meal timing:</strong> choose a consistent eating window; avoid large late-night meals when possible.</li>
    <li><strong>Meal sequencing:</strong> vegetables/fiber first, then protein, then starch. Many people see smaller glucose spikes and better fullness.</li>
    <li><strong>Protein floor:</strong> include protein at each meal. Many adults do well aiming for roughly 25–40 g per meal (individualize based on size, kidney status, and goals).</li>
    <li><strong>Fiber ramp:</strong> gradually increase fiber toward ~25–38 g/day (food-first). Hydration is essential.</li>
    <li><strong>Liquid calories:</strong> eliminate sugar-sweetened beverages and minimize calorie-dense coffee drinks.</li>
    <li><strong>Sleep anchor:</strong> set a consistent wake time; prioritize morning light exposure and a wind-down routine.</li>
  </ul>

  <h4>Step 2 (weeks 3–8): Protect muscle and improve insulin sensitivity</h4>
  <ul class="amh-list">
    <li><strong>Resistance training:</strong> 2–4 sessions/week; focus on large muscle groups; progression matters more than perfection.</li>
    <li><strong>Aerobic base:</strong> low-to-moderate intensity movement most days; walking is fine, cycling/elliptical are excellent if joints are sensitive.</li>
    <li><strong>Post-meal walking:</strong> 10–15 minutes after meals often produces outsized glycemic benefits.</li>
    <li><strong>Protein + training during therapy:</strong> if appetite drops on medication, plan protein intentionally to reduce lean mass loss risk.</li>
  </ul>

  <h4>Step 3 (months 2–6): Add targeted tools based on response and risk</h4>
  <ul class="amh-list">
    <li><strong>CGM (select cases):</strong> identify “problem meals,” late-night patterns, and the impact of alcohol/sleep loss.</li>
    <li><strong>Supplements (select cases):</strong> consider fiber supplements, berberine, or other options when diet is strong but numbers remain stubborn.</li>
    <li><strong>Medication escalation:</strong> consider incretin therapy when risk is meaningful and lifestyle alone is not achieving targets.</li>
  </ul>

  <div class="clinical-note">
    <strong>Medication reality check:</strong>
    Incretin medications can reduce appetite dramatically. The winning strategy is to use that window to build a high-protein, high-fiber,
    strength-training-supported lifestyle that is durable long-term. Without that, weight regain is common after stopping therapy.
  </div>

  <h3 id="treatments">Conventional treatments</h3>
  <p>
    Conventional incretin therapies are among the most effective pharmacologic tools for weight loss and glucose control.
    They are metabolic therapies requiring appropriate screening, titration, and monitoring. The details below are educational and non-prescriptive;
    your clinician will individualize dosing and monitoring to your needs.
  </p>

  <div class="alert-box">
    <strong>Safety first:</strong>
    If you use insulin or a sulfonylurea (medications that can cause hypoglycemia), adding GLP-1/GIP therapy changes hypoglycemia risk and typically requires medication adjustments.
    If you have a history of pancreatitis, gallbladder disease, severe gastroparesis, or a personal/family history of medullary thyroid cancer or MEN2, these therapies may be inappropriate.
  </div>

  <h4>Medication class overview (how these fit into care)</h4>
  <ul class="amh-list">
    <li><strong>GLP-1 receptor agonists (GLP-1 RA):</strong> used for type 2 diabetes and/or chronic weight management; several agents are weekly injections.</li>
    <li><strong>Dual GIP/GLP-1 receptor agonists:</strong> activate both pathways; can drive larger average weight loss in many individuals.</li>
    <li><strong>DPP-4 inhibitors (context):</strong> oral medications that reduce breakdown of endogenous incretins; generally less potent for weight loss.</li>
  </ul>

  <div class="rx-card amh-rx-card">
    <div class="rx-header">
      <div class="rx-name">Semaglutide (GLP-1 RA)</div>
      <div class="rx-type">STANDARD</div>
    </div>
    <div class="rx-grid">
      <div class="rx-label">What it is</div>
      <div>A potent GLP-1 receptor agonist used for type 2 diabetes and chronic weight management (different brand names and dosing protocols).</div>

      <div class="rx-label">How it works</div>
      <div>Enhances satiety and reduces appetite drive, slows gastric emptying, and improves glucose-dependent insulin secretion and glucagon regulation.</div>

      <div class="rx-label">Typical use</div>
      <div>Common regimens use gradual monthly dose increases to improve tolerability; weekly injection for diabetes and for weight management (regimen depends on indication and product).</div>

      <div class="rx-label">Common side effects</div>
      <div>Nausea, constipation, diarrhea, reflux, reduced appetite, fatigue; symptoms are often dose-related and improve with slower titration and smaller meals.</div>

      <div class="rx-label">Serious risks / cautions</div>
      <div>Gallbladder disease, pancreatitis (rare), worsening of severe gastroparesis, dehydration-related kidney injury (often in the setting of vomiting/poor intake); avoid with medullary thyroid cancer/MEN2 history.</div>

      <div class="rx-label">Monitoring</div>
      <div>Weight and symptoms; A1c/glucose if diabetes/prediabetes; kidney function if dehydration risk; consider gallbladder evaluation if persistent right-upper-quadrant pain.</div>

      <div class="rx-label">Typical cost</div>
      <div>Often expensive without insurance coverage; cash pricing frequently exceeds several hundred to over a thousand dollars per month depending on product and dose.</div>
    </div>
  </div>

  <div class="rx-card amh-rx-card">
    <div class="rx-header">
      <div class="rx-name">Tirzepatide (dual GIP/GLP-1)</div>
      <div class="rx-type">STANDARD</div>
    </div>
    <div class="rx-grid">
      <div class="rx-label">What it is</div>
      <div>A dual agonist that activates both GIP and GLP-1 pathways; used for type 2 diabetes and chronic weight management in appropriate patients.</div>

      <div class="rx-label">How it works</div>
      <div>Combines GLP-1–mediated appetite/gastric effects with GIP pathway activation; can produce greater average weight loss than GLP-1 alone in many studies.</div>

      <div class="rx-label">Typical use</div>
      <div>Typically started at a low dose and increased in stepwise fashion about every 4 weeks as tolerated; weekly injection; titration pace is individualized.</div>

      <div class="rx-label">Common side effects</div>
      <div>Nausea, constipation, diarrhea, decreased appetite, reflux; similar GI profile to GLP-1 therapy, often dose related.</div>

      <div class="rx-label">Serious risks / cautions</div>
      <div>Similar cautions as GLP-1 therapy: gallbladder disease, pancreatitis (rare), severe delayed gastric emptying; avoid with medullary thyroid cancer/MEN2 history.</div>

      <div class="rx-label">Monitoring</div>
      <div>Weight, symptoms, glucose/A1c, hydration status; medication adjustments if combined with other agents that can cause hypoglycemia.</div>

      <div class="rx-label">Typical cost</div>
      <div>Often expensive without coverage; out-of-pocket costs can be substantial and vary widely by insurance, coupons, and dosing.</div>
    </div>
  </div>

  <div class="rx-card amh-rx-card">
    <div class="rx-header">
      <div class="rx-name">Liraglutide (GLP-1 RA; daily injection)</div>
      <div class="rx-type">STANDARD</div>
    </div>
    <div class="rx-grid">
      <div class="rx-label">What it is</div>
      <div>A GLP-1 receptor agonist with daily injection dosing; used for diabetes and for weight management in certain protocols.</div>

      <div class="rx-label">How it works</div>
      <div>GLP-1 receptor activation improves satiety and glucose regulation via pancreatic and central appetite pathways.</div>

      <div class="rx-label">Typical use</div>
      <div>Daily dosing; titrated gradually; some patients prefer daily dosing flexibility or use when weekly options are not suitable.</div>

      <div class="rx-label">Common side effects</div>
      <div>Nausea and GI upset are common early; constipation or diarrhea may occur.</div>

      <div class="rx-label">Serious risks / cautions</div>
      <div>Similar class cautions as other GLP-1 agents; avoid in medullary thyroid cancer/MEN2 history; caution with severe GI motility disorders.</div>

      <div class="rx-label">Typical cost</div>
      <div>Varies; may be less or more expensive depending on formulation and insurance coverage.</div>
    </div>
  </div>

  <div class="rx-card amh-rx-card">
    <div class="rx-header">
      <div class="rx-name">Dulaglutide / Exenatide (GLP-1 RA; weekly options)</div>
      <div class="rx-type">STANDARD</div>
    </div>
    <div class="rx-grid">
      <div class="rx-label">What it is</div>
      <div>Weekly injectable GLP-1 receptor agonists typically used for type 2 diabetes; weight effects vary by agent and dose.</div>

      <div class="rx-label">How it works</div>
      <div>GLP-1 receptor activation improves glucose-dependent insulin secretion, appetite signaling, and slows gastric emptying.</div>

      <div class="rx-label">Typical use</div>
      <div>Weekly injection; titration differs by product; sometimes selected based on diabetes control needs, tolerance, or formulary coverage.</div>

      <div class="rx-label">Common side effects</div>
      <div>GI side effects similar to the class (nausea, constipation/diarrhea), usually highest during dose escalation.</div>

      <div class="rx-label">Serious risks / cautions</div>
      <div>Class warnings apply; some agents have renal dosing considerations and are not ideal in advanced kidney disease.</div>

      <div class="rx-label">Typical cost</div>
      <div>Generally brand-name pricing; insurance coverage and manufacturer programs strongly influence out-of-pocket cost.</div>
    </div>
  </div>

  <h4>Practical “how-to” for tolerability (works for many patients)</h4>
  <ul class="amh-list">
    <li><strong>Go slow:</strong> most GI side effects are dose-related; slower titration reduces dropouts.</li>
    <li><strong>Small, protein-forward meals:</strong> large fatty meals often trigger nausea; prioritize lean protein and cooked vegetables early in therapy.</li>
    <li><strong>Hydration + electrolytes:</strong> dehydration worsens nausea and constipation; plan fluids intentionally.</li>
    <li><strong>Constipation prevention:</strong> fiber, prunes/kiwi, adequate fluids, and movement; consider fiber supplements if tolerated.</li>
    <li><strong>Strength training:</strong> protects muscle and helps counter “skinny fat” weight loss; pair with adequate protein.</li>
    <li><strong>Alcohol caution:</strong> alcohol can worsen nausea/reflux and adds calories; it also increases pancreatitis risk in susceptible individuals.</li>
  </ul>

  <div class="clinical-note">
    <strong>Peri-procedure note:</strong>
    Because these medications can slow gastric emptying, clinicians may adjust dosing around procedures requiring anesthesia or sedation.
    Current guidance is evolving; the right approach depends on symptoms, dose-escalation phase, and procedure risk. Always inform your surgical/anesthesia team about incretin therapy.
  </div>

  <div class="alert-box">
    <strong>Avoid risky sourcing:</strong>
    Non–FDA-approved compounded “incretin” products have uncertain content and quality. If a product is not FDA-approved, the dose, purity, and safety are harder to verify.
    Discuss any non-standard sourcing with your clinician.
  </div>

  <h3 id="integrative">Integrative options</h3>
  <p>
    Integrative approaches can support endogenous GLP-1/GIP signaling through meal structure, fermentable fibers, selective protein strategies,
    and a short list of supplements with plausible mechanisms. The goal is not to “replace” medications when they are clinically indicated,
    but to improve physiology and reduce the need for escalation over time.
  </p>

  <h4>Food-first approaches (high ROI)</h4>

  <div class="rx-card amh-rx-card">
    <div class="rx-header">
      <div class="rx-name">Soluble fiber (food-first, then psyllium if needed)</div>
      <div class="rx-type">INTEGRATIVE</div>
    </div>
    <div class="rx-grid">
      <div class="rx-label">Rationale</div>
      <div>Soluble fiber slows glucose absorption, improves satiety, and feeds beneficial gut microbes that produce metabolites supporting gut hormone signaling.</div>

      <div class="rx-label">How it may work</div>
      <div>Forms a viscous gel that reduces glucose spikes; fermentation produces short-chain fatty acids that can influence enteroendocrine signaling.</div>

      <div class="rx-label">Typical use</div>
      <div>Start with fiber-rich foods (beans/lentils, oats, chia/flax, vegetables). If using psyllium, start low and increase slowly; take with a full glass of water.</div>

      <div class="rx-label">Side effects / cautions</div>
      <div>Bloating or gas if increased too fast; constipation if hydration is inadequate. Separate from medications by at least 2 hours if absorption is a concern.</div>

      <div class="rx-label">Typical cost</div>
      <div>Food-first is low cost; psyllium often costs roughly $10–$25/month depending on brand and dose.</div>
    </div>
  </div>

  <div class="rx-card amh-rx-card">
    <div class="rx-header">
      <div class="rx-name">Resistant starch + legumes</div>
      <div class="rx-type">INTEGRATIVE</div>
    </div>
    <div class="rx-grid">
      <div class="rx-label">Rationale</div>
      <div>Resistant starch behaves like a prebiotic fiber, improving satiety and post-meal glucose handling and potentially supporting gut hormone pathways.</div>

      <div class="rx-label">How it may work</div>
      <div>Fermentation products (short-chain fatty acids) may improve insulin sensitivity and gut-brain signaling; legumes also provide protein and micronutrients.</div>

      <div class="rx-label">Typical use</div>
      <div>Beans/lentils most days if tolerated; consider “cook-and-cool” starches (cooled potatoes/rice) for more resistant starch; increase gradually.</div>

      <div class="rx-label">Side effects / cautions</div>
      <div>Gas/bloating if ramped too quickly; consider soaking beans and gradual dose escalation.</div>

      <div class="rx-label">Typical cost</div>
      <div>Generally low cost; legumes are among the best nutrition-per-dollar options in metabolic health.</div>
    </div>
  </div>

  <div class="rx-card amh-rx-card">
    <div class="rx-header">
      <div class="rx-name">Protein “starter” (especially whey or a high-protein first course)</div>
      <div class="rx-type">INTEGRATIVE</div>
    </div>
    <div class="rx-grid">
      <div class="rx-label">Rationale</div>
      <div>A protein-forward starter can reduce hunger and blunt post-meal glucose spikes; certain proteins may amplify satiety hormone release.</div>

      <div class="rx-label">How it may work</div>
      <div>Protein slows gastric emptying and promotes satiety signals; amino acids and gut sensing can influence incretin release and appetite regulation.</div>

      <div class="rx-label">Typical use</div>
      <div>10–25 g protein before the highest-carb meal (e.g., Greek yogurt, eggs, lean meat, or whey protein in water). Adjust to tolerability.</div>

      <div class="rx-label">Side effects / cautions</div>
      <div>Context matters in kidney disease; some protein powders include additives; choose simple formulations. Whey may aggravate acne in some individuals.</div>

      <div class="rx-label">Typical cost</div>
      <div>Food-based protein varies; whey protein typically costs roughly $20–$60/month depending on brand and serving size.</div>
    </div>
  </div>

  <div class="rx-card amh-rx-card">
    <div class="rx-header">
      <div class="rx-name">Meal sequencing and slower eating</div>
      <div class="rx-type">INTEGRATIVE</div>
    </div>
    <div class="rx-grid">
      <div class="rx-label">Rationale</div>
      <div>Eating vegetables/fiber and protein first, then starch, can reduce glucose spikes and improve satiety; slowing down gives gut hormones time to signal fullness.</div>

      <div class="rx-label">How it may work</div>
      <div>Alters nutrient delivery rate to the small intestine, dampening rapid glucose absorption and supporting satiety hormone patterns; improves mindful intake.</div>

      <div class="rx-label">Typical use</div>
      <div>Start meals with vegetables, then protein, then carbs. Aim for 15–20 minutes per meal. Put the fork down between bites.</div>

      <div class="rx-label">Side effects / cautions</div>
      <div>Generally safe; consistency is the challenge. For reflux, avoid very large late meals and consider smaller portions.</div>

      <div class="rx-label">Typical cost</div>
      <div>No added cost.</div>
    </div>
  </div>

  <div class="rx-card amh-rx-card">
    <div class="rx-header">
      <div class="rx-name">Bitter greens and “bitters” (caution with reflux)</div>
      <div class="rx-type">INTEGRATIVE</div>
    </div>
    <div class="rx-grid">
      <div class="rx-label">Rationale</div>
      <div>Bitter taste receptors exist in the gut and may influence gut hormone secretion pathways in preclinical models. Human data are emerging and effects are likely modest.</div>

      <div class="rx-label">How it may work</div>
      <div>Bitter receptor activation in enteroendocrine cells can influence signaling that intersects with GLP-1 secretion; effects likely depend on compound and dose.</div>

      <div class="rx-label">Typical use</div>
      <div>Food-first: arugula, dandelion greens, radicchio, endive. Some people use alcohol-free bitters before meals, but this should be individualized and is not essential.</div>

      <div class="rx-label">Side effects / cautions</div>
      <div>May worsen reflux in some; avoid if it triggers symptoms. Consider medication interactions in complex regimens.</div>

      <div class="rx-label">Typical cost</div>
      <div>Low cost for bitter greens; bitters vary widely (often $10–$25 per bottle).</div>
    </div>
  </div>

  <h4>Supplements with plausible incretin or metabolic support (select cases)</h4>

  <div class="rx-card amh-rx-card">
    <div class="rx-header">
      <div class="rx-name">Berberine</div>
      <div class="rx-type">INTEGRATIVE</div>
    </div>
    <div class="rx-grid">
      <div class="rx-label">Rationale</div>
      <div>Often used for glucose control and insulin sensitivity; may influence gut microbiome and bile acid signaling that intersect with incretin physiology.</div>

      <div class="rx-label">How it may work</div>
      <div>Reduces hepatic glucose output and improves insulin sensitivity through multiple pathways; may alter gut microbial metabolites.</div>

      <div class="rx-label">Typical use</div>
      <div>Commonly taken with meals; start low to assess GI tolerance. Dosing and product quality vary.</div>

      <div class="rx-label">Side effects / cautions</div>
      <div>GI upset is common early. Potential interactions with many medications; avoid in pregnancy/breastfeeding unless specifically directed by a clinician.</div>

      <div class="rx-label">Typical cost</div>
      <div>Often $20–$60/month depending on dose and brand; quality testing is important.</div>
    </div>
  </div>

  <div class="rx-card amh-rx-card">
    <div class="rx-header">
      <div class="rx-name">Fenugreek seed (food) or standardized extract (supplement)</div>
      <div class="rx-type">INTEGRATIVE</div>
    </div>
    <div class="rx-grid">
      <div class="rx-label">Rationale</div>
      <div>Fenugreek has a long history of use in glycemic support. Certain extracts/compounds have been studied for interaction with GLP-1 receptor signaling.</div>

      <div class="rx-label">How it may work</div>
      <div>May influence glucose absorption and insulin signaling; specific compounds have been explored as modulators of GLP-1 receptor signaling in preclinical models.</div>

      <div class="rx-label">Typical use</div>
      <div>Food-first is preferred (fenugreek in cooking). If using an extract, use a time-limited trial with clear outcome tracking (CGM, fasting glucose, A1c trend).</div>

      <div class="rx-label">Side effects / cautions</div>
      <div>GI upset and gas are common; may lower glucose and increase hypoglycemia risk when combined with glucose-lowering medications. Avoid in pregnancy unless clinician-directed.</div>

      <div class="rx-label">Typical cost</div>
      <div>As a spice, minimal cost; extracts often ~$10–$40/month.</div>
    </div>
  </div>

  <div class="rx-card amh-rx-card">
    <div class="rx-header">
      <div class="rx-name">Green tea (or green tea extract)</div>
      <div class="rx-type">INTEGRATIVE</div>
    </div>
    <div class="rx-grid">
      <div class="rx-label">Rationale</div>
      <div>Green tea polyphenols may modestly improve insulin resistance and may influence GLP-1 patterns in some studies. It is also a low-calorie beverage replacement strategy.</div>

      <div class="rx-label">How it may work</div>
      <div>Polyphenols (including EGCG) may influence oxidative stress, insulin signaling, and enzymes involved in incretin metabolism in some models.</div>

      <div class="rx-label">Typical use</div>
      <div>2–4 cups/day of brewed green tea is a reasonable “food-first” approach. Extract supplements are optional and should be clinician-reviewed due to liver risk at high doses.</div>

      <div class="rx-label">Side effects / cautions</div>
      <div>Caffeine sensitivity, reflux, and sleep disruption if taken late. High-dose extracts have been associated with rare liver injury; avoid megadoses.</div>

      <div class="rx-label">Typical cost</div>
      <div>Tea is low cost; extracts often $10–$40/month.</div>
    </div>
  </div>

  <div class="rx-card amh-rx-card">
    <div class="rx-header">
      <div class="rx-name">Yerba maté (Ilex paraguariensis)</div>
      <div class="rx-type">INTEGRATIVE</div>
    </div>
    <div class="rx-grid">
      <div class="rx-label">Rationale</div>
      <div>Yerba maté is a traditional beverage with polyphenols and caffeine; preclinical data suggest effects on metabolism and potentially incretin pathways, with emerging human research.</div>

      <div class="rx-label">How it may work</div>
      <div>May influence appetite, insulin signaling, and gut microbial metabolites; incretin-related effects have been explored in animal and mechanistic studies.</div>

      <div class="rx-label">Typical use</div>
      <div>As a beverage earlier in the day (to protect sleep). Consider it a “swap” for caloric drinks rather than a stand-alone weight-loss intervention.</div>

      <div class="rx-label">Side effects / cautions</div>
      <div>Caffeine sensitivity, anxiety, or sleep disruption; avoid very hot beverages and very high intake. Use caution with reflux.</div>

      <div class="rx-label">Typical cost</div>
      <div>Typically low-to-moderate cost ($5–$25/month depending on use).</div>
    </div>
  </div>

  <div class="rx-card amh-rx-card">
    <div class="rx-header">
      <div class="rx-name">Curcumin (turmeric extract)</div>
      <div class="rx-type">INTEGRATIVE</div>
    </div>
    <div class="rx-grid">
      <div class="rx-label">Rationale</div>
      <div>Anti-inflammatory and insulin-sensitivity supportive effects in some studies; may indirectly support glycemic control when inflammation is a key driver.</div>

      <div class="rx-label">How it may work</div>
      <div>Modulates inflammatory signaling and oxidative stress; some formulations improve absorption and may influence metabolic markers.</div>

      <div class="rx-label">Typical use</div>
      <div>Often taken daily with food; formulations vary. Start low if GI sensitivity exists.</div>

      <div class="rx-label">Side effects / cautions</div>
      <div>May worsen reflux; caution with anticoagulants/antiplatelets; avoid high-dose use before procedures unless cleared by your clinician.</div>

      <div class="rx-label">Typical cost</div>
      <div>Often $15–$50/month depending on formulation and dose.</div>
    </div>
  </div>

  <div class="rx-card amh-rx-card">
    <div class="rx-header">
      <div class="rx-name">Ginseng (Panax species)</div>
      <div class="rx-type">INTEGRATIVE</div>
    </div>
    <div class="rx-grid">
      <div class="rx-label">Rationale</div>
      <div>Used traditionally for energy and metabolic support; evidence suggests modest glucose effects in select populations.</div>

      <div class="rx-label">How it may work</div>
      <div>May influence insulin secretion/sensitivity and oxidative stress; effects vary by species and preparation.</div>

      <div class="rx-label">Typical use</div>
      <div>Often taken in the morning; consider time-limited trials with clear goals (A1c trend, fasting glucose, CGM response).</div>

      <div class="rx-label">Side effects / cautions</div>
      <div>Can cause insomnia or jitteriness; may interact with anticoagulants and some psychiatric medications. Avoid in uncontrolled hypertension without clinician input.</div>

      <div class="rx-label">Typical cost</div>
      <div>Often $15–$50/month depending on extract quality and dose.</div>
    </div>
  </div>

  <div class="rx-card amh-rx-card">
    <div class="rx-header">
      <div class="rx-name">Probiotics / fermented foods (adjunct)</div>
      <div class="rx-type">INTEGRATIVE</div>
    </div>
    <div class="rx-grid">
      <div class="rx-label">Rationale</div>
      <div>Gut microbial composition and fermentation products influence appetite and glucose regulation. Fermented foods can be a low-risk adjunct for many people.</div>

      <div class="rx-label">How it may work</div>
      <div>May improve gut barrier function and microbial metabolites; effects are strain- and diet-dependent.</div>

      <div class="rx-label">Typical use</div>
      <div>Food-first: unsweetened yogurt/kefir, kimchi, sauerkraut, fermented vegetables. Supplements are optional and should be time-limited with outcome tracking.</div>

      <div class="rx-label">Side effects / cautions</div>
      <div>Bloating/gas in some. Use caution in severe immunosuppression. Choose low-sugar options.</div>

      <div class="rx-label">Typical cost</div>
      <div>Fermented foods vary; probiotic supplements commonly $20–$60/month.</div>
    </div>
  </div>

  <div class="clinical-note">
    <strong>Important perspective:</strong>
    “Natural incretin support” is primarily about physiology: meal structure, protein and fiber, timing, movement, and sleep.
    Supplements are adjuncts—not replacements for comprehensive metabolic care. If you are seeking medication-level appetite suppression,
    supplements generally will not replicate that effect, and chasing stronger effects can create safety risks.
  </div>

  <h3 id="costs">Cost considerations</h3>
  <p>
    Costs vary widely by insurance coverage, supply, indication, and dosing. Branded incretin medications are among the most expensive outpatient therapies.
    A pragmatic approach is to prioritize high-ROI foundations first, then use medications when risk reduction and health improvements justify the expense.
  </p>

  <ul class="amh-list">
    <li><strong>High-ROI, low-cost:</strong> meal structure, protein and fiber targets, post-meal walking, resistance training, sleep/circadian alignment.</li>
    <li><strong>Moderate cost:</strong> short-term CGM, dietitian coaching, gym or home equipment, selected supplements (fiber, berberine trial).</li>
    <li><strong>High cost:</strong> branded GLP-1 or dual GIP/GLP-1 therapy without insurance; long-term maintenance planning matters.</li>
  </ul>

  <div class="clinical-note">
    <strong>Value framing:</strong>
    For higher-risk patients (established cardiovascular disease, worsening diabetes, severe obesity, sleep apnea, fatty liver with fibrosis risk),
    incretin therapy may deliver “downstream” value by lowering complication risk. For lower-risk patients, lifestyle-first approaches often provide substantial benefit at far lower cost,
    albeit typically with slower and more effort-dependent results.
  </div>

  <h3 id="faq">FAQ</h3>

  <h4>Are there true “natural GLP-1 or GIP mimics”?</h4>
  <p>
    Some foods and supplements can increase endogenous GLP-1 release or influence incretin metabolism, but the magnitude is usually modest compared with prescription agents.
    The most reliable “natural incretin support” comes from meal structure (protein and fiber), meal timing, movement after eating, and sleep/circadian alignment.
  </p>

  <h4>Will GLP-1/GIP medications cause muscle loss?</h4>
  <p>
    Any meaningful weight loss can include lean mass loss, especially if appetite suppression lowers protein intake and resistance training volume.
    The countermeasure is intentional protein intake, progressive resistance training, and appropriate rate-of-loss goals.
  </p>

  <h4>Do I have to take these medications forever?</h4>
  <p>
    Not always, but many people regain weight after stopping because appetite and food-environment pressures return.
    Think of medication as a tool that can create a “behavior change window.” The more durable the foundations you build during that window, the more resilient your results will be.
  </p>

  <h4>What is the biggest mistake people make on incretin therapy?</h4>
  <p>
    Relying on appetite suppression alone while neglecting protein, fiber, hydration, and strength training. That increases side effects and lean mass loss risk,
    and it makes weight regain more likely when therapy changes.
  </p>

  <h4>What about compounded or “online” incretin products?</h4>
  <p>
    Be cautious. If a product is not FDA-approved, quality and dosing certainty are lower. Discuss any non-standard sourcing with your clinician.
  </p>


  <h3 id="references">References</h3>

    <ol class="ref-list">
  <li>American Diabetes Association. Standards of Care in Diabetes—2025 (guideline hub). <a href="https://professional.diabetes.org/standards-of-care" target="_blank" rel="noopener">https://professional.diabetes.org/standards-of-care</a></li>
  <li>Centers for Disease Control and Prevention. Prediabetes overview and diagnostic thresholds. <a href="https://www.cdc.gov/diabetes/basics/prediabetes.html" target="_blank" rel="noopener">https://www.cdc.gov/diabetes/basics/prediabetes.html</a></li>
  <li>FDA. Wegovy (semaglutide) prescribing information (label PDF). <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s011lbl.pdf" target="_blank" rel="noopener">https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s011lbl.pdf</a></li>
  <li>FDA. Zepbound (tirzepatide) prescribing information (label PDF). <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s003lbl.pdf" target="_blank" rel="noopener">https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s003lbl.pdf</a></li>
  <li>FDA press release: Wegovy approved to reduce risk of major cardiovascular events in adults with established CVD and overweight/obesity (Mar 8, 2024). <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or" target="_blank" rel="noopener">https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or</a></li>
  <li>FDA press release: Zepbound approved for obstructive sleep apnea in adults with obesity (Dec 20, 2024). <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea" target="_blank" rel="noopener">https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea</a></li>
  <li>American Society of Anesthesiologists. New multi-society guidance on GLP-1 receptor agonists before elective surgery (Oct 29, 2024). <a href="https://www.asahq.org/about-asa/newsroom/news-releases/2024/10/new-multi-society-glp-1-guidance" target="_blank" rel="noopener">https://www.asahq.org/about-asa/newsroom/news-releases/2024/10/new-multi-society-glp-1-guidance</a></li>
  <li>Kindel TL, et al. Multi-society clinical practice guidance for safe use of GLP-1 receptor agonists in the perioperative period (PubMed). <a href="https://pubmed.ncbi.nlm.nih.gov/39370500/" target="_blank" rel="noopener">https://pubmed.ncbi.nlm.nih.gov/39370500/</a></li>
  <li>American Diabetes Association statement: compounded GLP-1 and dual GIP/GLP-1 products (Dec 2, 2024). <a href="https://diabetes.org/newsroom/press-releases/american-diabetes-association-announces-statement-compounded-incretin" target="_blank" rel="noopener">https://diabetes.org/newsroom/press-releases/american-diabetes-association-announces-statement-compounded-incretin</a></li>
  <li>NIH Office of Dietary Supplements. Dietary fiber (health professional fact sheet). <a href="https://ods.od.nih.gov/factsheets/DietaryFiber-HealthProfessional/" target="_blank" rel="noopener">https://ods.od.nih.gov/factsheets/DietaryFiber-HealthProfessional/</a></li>
  <li>NIH NCCIH. Turmeric (curcumin): in-depth overview. <a href="https://www.nccih.nih.gov/health/turmeric" target="_blank" rel="noopener">https://www.nccih.nih.gov/health/turmeric</a></li>
  <li>NIH NCCIH. Probiotics: what you need to know. <a href="https://www.nccih.nih.gov/health/probiotics-what-you-need-to-know" target="_blank" rel="noopener">https://www.nccih.nih.gov/health/probiotics-what-you-need-to-know</a></li>
  <li>King K, et al. Isolation of positive modulator of GLP-1 receptor from fenugreek seeds (open access). <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4646272/" target="_blank" rel="noopener">https://pmc.ncbi.nlm.nih.gov/articles/PMC4646272/</a></li>
  <li>Chou IW, et al. Fenugreek compound N55 and modulation of GLP-1 receptor signaling (Scientific Reports, 2017). <a href="https://www.nature.com/articles/s41598-017-12290-x" target="_blank" rel="noopener">https://www.nature.com/articles/s41598-017-12290-x</a></li>
  <li>Liu CY, et al. Effects of green tea extract on insulin resistance and GLP-1 (open access). <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3948786/" target="_blank" rel="noopener">https://pmc.ncbi.nlm.nih.gov/articles/PMC3948786/</a></li>
  <li>Harmon CP &amp; colleagues. Bitter taste receptors (T2Rs) and coordination of metabolic responses including GLP-1 (open access review). <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7963268/" target="_blank" rel="noopener">https://pmc.ncbi.nlm.nih.gov/articles/PMC7963268/</a></li>
  <li>Gambero A, et al. Review of yerba maté and obesity/metabolic effects (open access). <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4344557/" target="_blank" rel="noopener">https://pmc.ncbi.nlm.nih.gov/articles/PMC4344557/</a></li>
  <li>USDA Dietary Guidelines for Americans. <a href="https://www.dietaryguidelines.gov/" target="_blank" rel="noopener">https://www.dietaryguidelines.gov/</a></li>
  <li>American Heart Association. Healthy living and cardiometabolic risk foundations. <a href="https://www.heart.org/en/healthy-living" target="_blank" rel="noopener">https://www.heart.org/en/healthy-living</a></li>
  <li>GoodRx. Drug price lookup (for typical cash pricing context). <a href="https://www.goodrx.com/" target="_blank" rel="noopener">https://www.goodrx.com/</a></li></ol>

      <footer class="amh-footer">
        <div class="amh-disclaimer medical-disclaimer">
          <p><strong>Medical disclaimer:</strong> The information on this page is provided for general educational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease, and it does not establish a physician–patient relationship.</p>
          <p>Do not apply this information to your specific situation without the oversight of a qualified clinician who can consider your full health history, medications, goals, preferences, and limitations. If you have urgent or severe symptoms, seek emergency care.</p>
          <p style="margin: 0;"><strong>Copyright:</strong> © Dr. Bray at Archangel Michael Health <span id="amh-year">2025</span></p>
        </div>

        <div class="amh-footer-meta">
          <span><strong>Archangel Michael Health</strong> | Internal &amp; Integrative Medicine</span>
          <span class="amh-dot">•</span>
          <span><strong>Last updated:</strong> <span id="amh-last-updated">—</span></span>
        </div>
      </footer>
    </div>
  </div>

  <script>
    (function () {
      // ---- Last updated + year ----
      var yearEl = document.getElementById("amh-year");
      if (yearEl) {
        try { yearEl.textContent = String(new Date().getFullYear()); } catch (e) {}
      }

      var updatedEl = document.getElementById("amh-last-updated");
      if (updatedEl) {
        var lm = document.lastModified; // usually reflects server file Last-Modified (works well on GitHub Pages)
        var d = lm ? new Date(lm) : null;
        if (d && !isNaN(d.getTime())) {
          // ISO-like YYYY-MM-DD
          var yyyy = d.getFullYear();
          var mm = String(d.getMonth() + 1).padStart(2, "0");
          var dd = String(d.getDate()).padStart(2, "0");
          updatedEl.textContent = yyyy + "-" + mm + "-" + dd;
        } else {
          updatedEl.textContent = "—";
        }
      }

      // ---- TOC scrolling (support both anchor links and data-scroll buttons) ----
      function scrollToId(id) {
        var el = document.getElementById(id);
        if (!el) return;
        el.scrollIntoView({ behavior: "smooth", block: "start" });
      }

      document.addEventListener("click", function (e) {
        var btn = e.target.closest(".toc-btn[data-scroll]");
        if (btn) {
          e.preventDefault();
          scrollToId(btn.getAttribute("data-scroll"));
          return;
        }

        var link = e.target.closest('.toc a[href^="#"]');
        if (link) {
          var hash = link.getAttribute("href");
          var target = hash && hash.length > 1 ? hash.slice(1) : null;
          if (!target) return;
          e.preventDefault();
          scrollToId(target);
          history.replaceState(null, "", hash);
        }
      });

      // ---- Download PDF using html2pdf.js ----
      var btn = document.getElementById("downloadPdfBtn");
      if (!btn) return;

      function safeFilename(title) {
        return (title || "patient-guide")
          .toLowerCase()
          .replace(/[^a-z0-9]+/g, "-")
          .replace(/(^-|-$)/g, "");
      }

      btn.addEventListener("click", function () {
        if (typeof html2pdf === "undefined") {
          alert("PDF generator is still loading. Please try again in a moment, or use Print / Save as PDF.");
          return;
        }

        btn.disabled = true;
        btn.textContent = "Preparing PDF...";

        var title = (document.getElementById("page-title") && document.getElementById("page-title").textContent) || "Patient Guide";
        var filename = safeFilename(title) + ".pdf";

        // Clone content for PDF and remove UI elements
        var source = document.getElementById("pdf-root").cloneNode(true);
        source.querySelectorAll(".no-print").forEach(function (el) { el.remove(); });

        var wrapper = document.createElement("div");
        wrapper.style.background = "#ffffff";
        wrapper.appendChild(source);

        var opt = {
          margin: [0.5, 0.5, 0.6, 0.5], // inches
          filename: filename,
          image: { type: "jpeg", quality: 0.98 },
          html2canvas: { scale: 2, useCORS: true, letterRendering: true },
          jsPDF: { unit: "in", format: "letter", orientation: "portrait" },
          pagebreak: { mode: ["css", "legacy"] }
        };

        html2pdf()
          .set(opt)
          .from(wrapper)
          .save()
          .catch(function (err) {
            console.error(err);
            alert("Could not generate the PDF in this browser. Please use Print / Save as PDF.");
          })
          .finally(function () {
            btn.disabled = false;
            btn.textContent = "Download PDF";
          });
      });
    })();
  </script>
</body>
</html>
